Catherine Ann Malcolm Stedman is a New Zealand pharmacologist and gastroenterologist, and is a clinical professor at the University of Otago, specialising in hepatitis C drug development. She is the first woman gastroenterologist to become a professor of medicine in New Zealand.

Stedman completed her undergraduate medical degree at the University of Otago, and then undertook a PhD titled Role of nuclear receptors in bile acid disposition and detoxification at the University of Sydney in 2006. ^[1] Her clinical training in pharmacology and gastroenterology took place at Christchurch Hospital and Westmead Hospital in Sydney. ^[2] Stedman then worked in the Salk Institute, and on drug safety for a pharmaceutical company. ^[2] Stedman returned to Christchurch Hospital as a consultant gastroenterologist and joined the faculty of the University of Otago, rising to clinical associate professor in 2015 and full professor in 2023. ^{[3] [4]} She is the first woman gastroenterologist to become a professor of medicine in New Zealand. ^[2]

Stedman's research focuses on drug development for hepatitis C treatment, although she is also interested in autoimmune liver diseases, and how they affect the lives and life expectancy of people who have them. Stedman has been a principal investigator in a large number of clinical trials aimed at testing antiviral therapies, and led the first successful clinical trial in the world to show that oral antiviral treatment could cure hepatitis C. ^[4] Stedman has also led trials for antiviral therapies aimed at patients with liver failure resulting from hepatitis C. ^[4] As a result of these trials, and other potential therapies, the World Health Organization has proposed elimination of hepatitis C. ^{[4] [5] [6] [7]}

As of 2024, Stedman is the president of the New Zealand Society of Gastroenterology. ^[2]

In 2019 Stedman was awarded the Gold Research Medal by the University of Otago Christchurch campus. ^[8]

Scholia has a profile for Catherine Stedman (Q115736169).

• Graham R Foster; Nezam Afdhal; Stuart K Roberts; et al. (17 November 2015). "Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection". The New England Journal of Medicine. 373 (27): 2608–2617. doi: 10.1056/NEJMOA1512612. ISSN  0028-4793. PMID  26575258. Wikidata  Q40907444.{{ cite journal}}: CS1 maint: numeric names: authors list ( link)
• Susanna Naggie; Curtis Cooper; Michael Saag; et al. (21 July 2015). "Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1". The New England Journal of Medicine. 373 (8): 705–713. doi: 10.1056/NEJMOA1501315. ISSN  0028-4793. PMC  4892372. PMID  26196665. Wikidata  Q36967076.{{ cite journal}}: CS1 maint: numeric names: authors list ( link)
• Edward J Gane; Stuart K Roberts; Catherine A M Stedman; et al. (14 October 2010). "Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial". The Lancet. 376 (9751): 1467–1475. doi: 10.1016/S0140-6736(10)61384-0. ISSN  0140-6736. PMID  20951424. Wikidata  Q42857015.
• Devin Razavi-Shearer; Ivane Gamkrelidze; Mindie H Nguyen; et al. (June 2018). "Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study". The lancet. Gastroenterology & hepatology. 3 (6): 383–403. doi: 10.1016/S2468-1253(18)30056-6. ISSN  2468-1253. PMID  29599078. Wikidata  Q56830540.
• Catherine A M Stedman; Christopher Liddle; Sally A Coulter; Junichiro Sonoda; Jacqueline G A Alvarez; David D Moore; Ronald M Evans; Michael Downes (31 January 2005). "Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury". Proceedings of the National Academy of Sciences of the United States of America. 102 (6): 2063–2068. Bibcode: 2005PNAS..102.2063S. doi: 10.1073/PNAS.0409794102. ISSN  0027-8424. PMC  548592. PMID  15684063. Wikidata  Q33838275.
• Catherine Stedman; Christopher Liddle; Sally Coulter; Junichiro Sonoda; Jacqueline G Alvarez; Ronald M Evans; Michael Downes (14 July 2006). "Benefit of farnesoid X receptor inhibition in obstructive cholestasis". Proceedings of the National Academy of Sciences of the United States of America. 103 (30): 11323–11328. Bibcode: 2006PNAS..10311323S. doi: 10.1073/PNAS.0604772103. ISSN  0027-8424. PMC  1544085. PMID  16844773. Wikidata  Q34983994.
• Ira M Jacobson; Eric Lawitz; Edward J Gane; et al. (5 April 2017). "Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials". Gastroenterology. 153 (1): 113–122. doi: 10.1053/J.GASTRO.2017.03.047. ISSN  0016-5085. PMID  28390869. Wikidata  Q40251971.
• Catherine Stedman (1 January 2002). "Herbal hepatotoxicity". Seminars in Liver Disease. 22 (2): 195–206. doi: 10.1055/S-2002-30104. ISSN  0272-8087. PMID  12016550. Wikidata  Q34643156.

• Hepatitis C and liver disease: The journey to cure and eliminate, Inaugural professorial lecture by Catherine Stedman, 3 May 2023, via YouTube
• Catherine Stedman on Clinical Trials for Hepatitis C, 2021, via Vimeo